
Allegheny Health Network cancer patients receiving support and hope from cancer survivor
A new program at Allegheny Health Network is helping cancer patients feel less isolated and anxious throughout their cancer journey by connecting them with someone who understands what they're going through.
The person behind the unique program is a three-time cancer survivor.
A cancer diagnosis can make people feel many emotions, including shock, stress, loneliness, and hope.
Terri Ronald of Hampton Township is a wife and mother, and she has been on that emotional rollercoaster three times.
"I had a melanoma when I was 39. Breast cancer at 46, and then breast cancer at 54," she said.
Ronald said her insurance company denied her MRI before her third cancer journey two years ago.
"Thank goodness I had a great surgeon at AHN who had to have a peer-to-peer with an insurance person to get that MRI authorized so that I could get that and they found my third cancer," Ronald said.
Her experience made her think about people who can't advocate for themselves.
"It kind of put a fire under me to start a program that would be very beneficial to people all over the community of cancer," said Ronald.
And now Ronald is the program manager of Allegheny Health Network Cancer Institute's community cancer patient ambassador program, which was created in August.
She said when a patient gets a cancer diagnosis, they're paired with someone who has walked in their shoes.
"I, through our clinical teams, will pair them with a cancer peer.. think of almost like a sponsor with cancer," Ronald said. "A cancer peer is someone who has had a very similar diagnosis prognosis treatment plan."
More than 20 volunteer patient ambassadors for several types of cancer have been trained and are helping patients and their families beyond hospital walls.
"We know what this is like. And when we say a peer, it's someone who has, I would say, gone to the other side. They're in survivorship. So, they can pull that person in and say, I did it. Look at me. And I'm going to give you all the practical advice that I can. And I'm going to listen. I'm going to be a reflective listener. And be an emotional support to that person. When they're feeling down, call them up. Challenging day, text them," said Ronald.
The volunteer ambassadors undergo extensive training and go through a formalized process that also includes reviewing protected health information, confidentiality, and HIPAA.
You could say the program's cancer peers are like cheerleaders, providing non-clinical support and resources, and hope and strength, and cheering on patients who are fighting their toughest battles.
"I can say to people, this is what cancer three times can be. You know, get your screenings. Don't be scared. We're really good at this," Ronald said.
"We know what helps people because we've walked the walk...It's being there to lift somebody up when they really need to be lifted up," she added.
Ronald is passionate about growing the program that's providing a vital lifeline for patients.
"We have about 15 breast cancer ambassadors. I have about eight for the rare and metastasized disease, which is a lot of appendiceal peritoneal disease. We have a few on board for blood cancers. We have a few on board for gynecological cancers. And we need to build out 14 cancer disease lines. So it's a lot of work," said Ronald.
If you beat cancer, or if your family member is a survivor and you want to help by becoming a Community Cancer Patient Ambassador at AHN, contact cancerambassadors@ahn.org to learn more.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 hours ago
- Yahoo
Pharmacy benefit managers wield significant influence over patient care, costs
Multiple Republican-led states have sued to rescind a federal rule keeping the records of those who sought legal reproductive care private, while a federal judge in Texas is questioning the constitutionality of the federal HIPAA law in its entirety. (Photo by) As a physician, I have witnessed firsthand the inefficiencies in our health care system that make it harder for patients to access the care they need. One of these complexities patients now have to navigate is a growing industry of insurance middlemen known as pharmacy benefit managers (PBMs), whose practices meddling in our local health system increase health care costs and block access to critical medications. PBMs work between health insurance companies and drug manufacturers to negotiate lower drug prices for the health plans they represent. Their function and influence in the health care industry have evolved significantly, and today, PBMs operate with very little oversight or transparency and their decisions are often based on what is most profitable for a health plan rather than what is best for a patient. PBMs wield significant influence over what treatments patients can access and how much they will be required to pay. These middlemen receive significant rebates and discounts from pharmaceutical manufacturers for the cost of medications and treatments after negotiations, but they don't pass those savings on to patients receiving the care, increasing what patients are required to pay out of pocket when they pick up their medication at the pharmacy counter. PBMs can also require only certain drugs be covered by a health plan, impose arbitrary rules around access to provider-prescribed medications, and PBM revenue is often directly linked to the list price of a medicine, so PBMs are incentivized to recommend treatments that would yield the most profit. The three largest PBMs – CVS Caremark, Express Scripts and OptumRx – manage nearly 80% of prescription drug claims for 270 million people across the country. To make matters worse, PBMs are increasingly integrating and consolidating with other health care services, including distributors and pharmacies, making the influence PBMs hold over the health care system even larger. As these for-profit entities merge and collaborate, it's unclear if the system is actually functioning in the best interest of patients regarding quality and cost of care. PBMs have flown under the radar for far too long, but scrutiny of these middlemen and their impact on our health care system has rightfully grown in recent years, with many federal and state policymakers and regulators calling attention to the outsized role PBMs play in driving up health care costs. The Federal Trade Commission (FTC) found that PBM integration with chain pharmacies and insurers has allowed them to dominate the broader health system and that PBMs have significant control over what drugs are available to patients and how much they are required to pay. The FTC even filed suit against the three of the nation's largest PBMs, citing their anticompetitive tactics as a barrier to health care access. In addition, numerous investigations found that PBMs often act in their own financial interest, including pushing patients toward drugs with higher out-of-pocket costs because it's more profitable for the PBM. Access to consistent treatments is necessary for Louisiana patients, particularly those living with chronic health conditions or hard-to-treat illnesses such as cancer. Each year, more than 25,000 Louisianans receive a new cancer diagnosis. Alleviating access and financial barriers to care is a necessary step to improving health outcomes for patients. It is overwhelmingly clear that we must take action to reform PBM practices to improve access to care for patients and stop letting middlemen meddle in our health system. There has never been a time when we can do more for patients as doctors, but at the same time, there has never been a time when we have more complexities in the health care systems impede healthcare access and affordability. This 'profit over patients' business model is putting critical care out of reach for many Louisiana patients. Time is overdue to curb harmful PBM practices.
Yahoo
20 hours ago
- Yahoo
Rocketseed launches essential email signature guide for healthcare organizations
New resource helps healthcare providers improve branded communication, ensure HIPAA compliance, and boost patient engagement through smart email signature management. CHARLOTTE, N.C., June 6, 2025 /PRNewswire/ -- Rocketseed, a global leader in business email signature management and marketing, has released a new comprehensive resource, Healthcare Email Signature Management: An Essential Guide. Specifically developed for hospitals, clinics, and other healthcare providers, the guide shows how professionally managed email signatures can support compliance, strengthen branding, and enhance communication across the sector, increasing engagement amongst both patients and staff. With healthcare professionals under increasing pressure to meet data protection regulations like HIPAA, maintain patient trust, promote new treatments and key services, and strengthen workplace inclusivity, this guide offers practical, actionable advice for IT leaders, marketers, and frontline staff alike to achieve these goals - all through everyday email. Helping Healthcare Providers Stay Professional, Compliant and ConnectedThe guide outlines how to design, manage and run marketing campaigns with email signatures and banners to meet specific healthcare industry challenges and maximize results. Key topics include: Best practice email signature design tips and examples for healthcare professionals, including doctors and administrators. Benefits of centralized signature management, including guaranteed brand consistency, and saving IT time through automating all staff signature updates. Importance of using HIPAA (plus ISO27001, GDPR and POPIA) compliant email signature management software to ensure patient confidentiality and data protection. Use of targeted, interactive email banners for promoting seasonal health campaigns, patient education, and new treatments and services - all illustrated with examples. Internal email banner use for HR, training, and strengthening workplace culture. Role of robust analytics and real-time reporting in measuring email signature and banner success and ROI. Rocketseed's platform is HIPAA compliant, works across all email clients (including Microsoft 365 and Google Workspace) and devices, and helps healthcare IT teams save hundreds of hours through automation and user directory synchronization. "In today's highly-regulated healthcare environment, clear and compliant communication is essential," says Damian Hamp-Adams, North America CEO at Rocketseed. "Our guide shows how email signatures - when centrally managed and professionally designed - can do more than meet HIPAA requirements. They become a trusted communication tool across the entire organization." Driving Engagement Through Data and DesignThe guide also explores how analytics and real-time reporting can optimize engagement. Healthcare organizations can track all recipient interactions with their email banners and signature content, enabling smarter campaign decisions, such as refining designs and optimizing targeting, to generate greater return on their communication efforts. "Our goal is to help healthcare providers meet compliance needs while turning every email into a powerful communication channel," adds Damian. "This guide shows that with the right tools, even email signatures can play a vital role in delivering better patient care and stronger internal communication." This new release joins Rocketseed's growing library of industry-focused resources, including essential guides for hotels & hospitality, transportation & logistics, insurance, pharmaceutical and construction industries - each tailored to the unique compliance, branding, and communication needs of their sectors. About Rocketseed Rocketseed is a leading provider of email signature management and marketing solutions, used and trusted by businesses worldwide. With tools for centralized signature control, automated updates, targeted banner campaigns, and robust analytics, Rocketseed helps organizations maintain brand consistency, drive engagement, and ensure compliance — all through their everyday email. Learn more at Jennifer 547354 View original content to download multimedia: SOURCE Rocketseed (United States) Inc


Medscape
a day ago
- Medscape
MRI-Led Surveillance Stratifies Prostate Cancer Risk
In a cohort study of patients with prostate cancer, MRI-led risk-adapted active surveillance demonstrated effectiveness in risk stratification. The approach showed that MRI visibility and the presence of secondary Gleason pattern 4 at baseline were associated with higher rates of progression and treatment initiation. METHODOLOGY: Researchers analysed 1150 patients who started active surveillance between February 2000 and July 2023, including those with a Gleason score (GS) ≤ 3 + 4, prostate-specific antigen (PSA) < 20 ng/mL, and at least two MRI scans. Participants underwent PSA testing three to four times in the first year, followed by biannual testing; MRI was performed at baseline and 12 months, with an additional MRI scan performed at 24 months for those with MRI-visible lesions at baseline. Patients were stratified into four groups on the basis of baseline risk factors, including GS (3 + 3 vs 3 + 4) and MRI visibility ("non-visible disease" vs "visible disease"). The primary outcome was event-free survival, with an event defined as the detection of GS ≥ 4 + 3 or the initiation of any prostate cancer treatment. The median follow-up duration was 64 months per person overall and 72 months for 732 patients without an event. At baseline, 64% of patients had GS 3 + 3 and 36% had GS 3 + 4; 49% of those with GS 3 + 4 had MRI-visible disease. TAKEAWAY: Event-free survival rates varied significantly on the basis of the risk group, with 5-year rates of 91% for non-visible GS 3 + 3, 71% for MRI-visible GS 3 + 3, 71% for non-visible GS 3 + 4, and 44% for MRI-visible GS 3 + 4 disease. Among 487 patients who underwent follow-up biopsies, histological upgrade to GS ≥ 4 + 3 occurred in 67 patients; non-visible GS 3 + 3 cases had 5- and 10-year rates of 1.2% and 6.1%, respectively, for histological progression to GS ≥ 4 + 3, while the rates were 17% and 43% for those with MRI-visible GS 3 + 4 disease at baseline, respectively. Progression to nodal or bone metastases was observed in 10 patients, occurring only in those who had declined recommended follow-up MRI and/or biopsies. The 10-year rate of commencing treatment was 28% for those with non-visible GS 3 + 3 disease vs 85% for those with MRI-visible GS 3 + 4 disease and 46% for those with non-visible GS 3 + 4 disease vs 54% for those with MRI-visible GS 3 + 3 disease. IN PRACTICE: "Results from our cohort suggest that AS [active surveillance] patients can be monitored safely with MRI, and the decision to biopsy was based on MRI findings and PSA changes. Prospective, multicentre, clinical trials are required and currently being designed to further evaluate this approach," the authors wrote. SOURCE: This study was led by Cameron Englman, Division of Surgery & Interventional Science, University College London, London, England. It was published online on May 27, 2025, in European Urology . LIMITATIONS: Compared with time-based biopsy protocols, the MRI-led risk-adapted approach may underestimate histological progression. Additionally, as a cohort study without a strict protocol, practice evolved alongside contemporary pathology and radiology standards, with MRI quality, reporting standards, and the definition of radiological progression varying over time, particularly improving after the adoption of the PRECISE recommendations in 2016. DISCLOSURES: This study did not receive any specific funding. Several authors reported receiving consulting fees and grants and having other ties with various sources.